Abstract:Immunobiologic therapy is indicated for severe forms of psoriasis, resistant to
conventional therapy. There is growing concern about their safety profile and
possible association with cancer development. This article documents two cases of
renal cell cancer during treatment with biologic therapy, reviewing what is described
in the literature . The risk of solid tumors as a complication of using TNF-alpha
inhibitors is controversial. No conclusion can be drawn from the data in the
literature, however, we believ… Show more
S Etanercept/infliximab Clear cell renal carcinoma and papillary renal carcinoma: 2 case reportsA 41-year-old man developed clear cell renal carcinoma during treatment with infliximab and a 66-year-old man developed papillary renal carcinoma during treatment with etanercept.The 41-year-old man, with a 11 year history of severe psoriasis and psoriatic arthritis, received methotrexate; however, his Psoriasis Area and Severity Index (PASI) remained at 28.9. Thus, infliximab 4 mg/kg [route not stated] was added to the treatment. At 108 weeks of infliximab, due to the development of jaundice and elevated transaminase levels he was diagnosed with hepatitis. An abdominal ultrasound revealed a mass in the right kidney and he underwent a total nephrectomy with a diagnosis of clear cell renal carcinoma by histopathological analysis. The surgery was curative and administration of leflunomide stabilized his joint symptoms and partially controlled the cutaneous lesions.The 66-year-old man with a 40 year history of psoriasis received methotrexate and was undergoing psoralen with UVA light therapy and taking acitretin; however, developed new cutaneous lesions and joint symptoms. Thus, leading to the initiation of etanercept 50 mg/week [route not stated]. After 218 weeks of etanercept, he underwent abdominal ultrasonography due to prostatic symptoms, which revealed a renal mass. He underwent a total nephrectomy with a diagnosis of papillary renal carcinoma by histopathological examination. Surgery was curative, and the administration of acitretin kept the disease under control.Author comment: "However, there is a growing concern about the safety profile, mainly due to the possible association of these drugs with an increased incidence of neoplasia. This article documents two cases of renal cell cancer during treatment with biologic therapy, reviewing the literature so far."Zarur FP, et al. Two cases of renal cell cancer during immunobiologic therapy for psoriasis. Anais Brasileiros de
S Etanercept/infliximab Clear cell renal carcinoma and papillary renal carcinoma: 2 case reportsA 41-year-old man developed clear cell renal carcinoma during treatment with infliximab and a 66-year-old man developed papillary renal carcinoma during treatment with etanercept.The 41-year-old man, with a 11 year history of severe psoriasis and psoriatic arthritis, received methotrexate; however, his Psoriasis Area and Severity Index (PASI) remained at 28.9. Thus, infliximab 4 mg/kg [route not stated] was added to the treatment. At 108 weeks of infliximab, due to the development of jaundice and elevated transaminase levels he was diagnosed with hepatitis. An abdominal ultrasound revealed a mass in the right kidney and he underwent a total nephrectomy with a diagnosis of clear cell renal carcinoma by histopathological analysis. The surgery was curative and administration of leflunomide stabilized his joint symptoms and partially controlled the cutaneous lesions.The 66-year-old man with a 40 year history of psoriasis received methotrexate and was undergoing psoralen with UVA light therapy and taking acitretin; however, developed new cutaneous lesions and joint symptoms. Thus, leading to the initiation of etanercept 50 mg/week [route not stated]. After 218 weeks of etanercept, he underwent abdominal ultrasonography due to prostatic symptoms, which revealed a renal mass. He underwent a total nephrectomy with a diagnosis of papillary renal carcinoma by histopathological examination. Surgery was curative, and the administration of acitretin kept the disease under control.Author comment: "However, there is a growing concern about the safety profile, mainly due to the possible association of these drugs with an increased incidence of neoplasia. This article documents two cases of renal cell cancer during treatment with biologic therapy, reviewing the literature so far."Zarur FP, et al. Two cases of renal cell cancer during immunobiologic therapy for psoriasis. Anais Brasileiros de
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.